Lipid-lowering medications: Fibrates

21,587views

00:00 / 00:00

Flashcards

Lipid-lowering medications: Fibrates

of complete

Questions

USMLE® Step 1 style questions USMLE

of complete

USMLE® Step 2 style questions USMLE

of complete

A 41-year-old man presents to the office for a routine follow-up. He is asymptomatic and feels well. Past medical history is significant for type II diabetes mellitus and hypertension. Current medications include metformin, simvastatin, and lisinopril. Family history is significant for myocardial infarction in the patient’s father. He smokes two packs of cigarettes daily and does not use alcohol or illicit drugs. Vitals are within normal limits. Physical examination reveals the findings shown below. Recent laboratory workup revealed an elevated triglyceride level and a normal liver function test. The patient is prescribed gemfibrozil for the management of hypertriglyceridemia. Which of the following is most helpful in monitoring for potential complications of statin and fibrate combination therapy?
 
Image reproduced from Wikimedia Commons

Memory Anchors and Partner Content

External References

First Aid

2024

2023

2022

2021

Bezafibrate p. 325

Transcript

Watch video only

Content Reviewers

Fibrates are a group of lipid-lowering medications, along with statins and niacin.

These medications are very effective at lowering triglyceride levels in the blood, but are less effective at controlling cholesterol.

Now, triglycerides make up most of your body fat, and they consist of a glycerol and 3 fatty acids.

So when we eat a box of chili fries, the fatty acids and cholesterol are absorbed into the cells in the small intestine.

The fatty acids are then converted into triglycerides.

However, triglycerides and cholesterol are not water soluble, so they can’t travel freely in the blood. To fix this, our body makes “shipping boxes” called lipoproteins.

These containers consist of a shell made of phospholipids and protein tags that act as instructions for their destination.

So after absorption, the small intestinal cells package the triglycerides and cholesterol into the largest, but least dense lipoproteins, called chylomicrons.

These are released into the lymphatic system and then enter the bloodstream via the subclavian vein. Then, they travel through the blood to reach the liver and other tissues in the body.

Now in the blood vessels near these tissues, we have an enzyme called lipoprotein lipase, which can break down triglycerides into fatty acids.

Cells in the nearby tissue can then use these fatty acids to generate ATP.

Adipose tissue can synthesize a lot of lipoprotein lipases, which means they have access to a lot of fatty acids.

Now, instead of using the fatty acids for energy, they pick them up, convert them back into triglycerides, and store them for later use.

Okay, so we can also synthesize fatty acids from glucose in the liver which are then converted into triglycerides.

These triglycerides and some cholesterol are packed into the next kind of lipoproteins called very-low-density lipoproteins or VLDL, which are smaller and more dense than chylomicrons.

This package is sent into the bloodstream to carry the energy-rich triglycerides to the rest of the body.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "PPAR Agonists and Metabolic Syndrome: An Established Role?" International Journal of Molecular Sciences (2018)
  5. "Fibrates for primary prevention of cardiovascular disease events" Cochrane Database of Systematic Reviews (2016)
  6. "PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy" Cancer Immunology Research (2018)
  7. "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study" BMJ (2019)
Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX